195 related articles for article (PubMed ID: 21559978)
1. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Sowa-Staszczak A; Pach D; Chrzan R; Trofimiuk M; Stefańska A; Tomaszuk M; Kołodziej M; Mikołajczak R; Pawlak D; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1669-74. PubMed ID: 21559978
[TBL] [Abstract][Full Text] [Related]
2. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
3. Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)--PRRT and long-acting somatostatin analogs as the neoadjuvant therapy.
Sowa-Staszczak A; Pach D; Stefańska A; Szybiński P; Kulig J; Tomaszewska R; Chrzan R; Hubalewska-Dydejczyk A
Nucl Med Rev Cent East Eur; 2012 Aug; 15(2):137-9. PubMed ID: 22936508
[TBL] [Abstract][Full Text] [Related]
4. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
Sowa-Staszczak A; Chrzan R; Pach D; Stefańska A; Tomaszuk M; Buziak-Bereza M; Kołodziej M; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
Clin Imaging; 2012; 36(4):360-4. PubMed ID: 22726975
[TBL] [Abstract][Full Text] [Related]
5. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
6. Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors.
Opalińska M; Sowa-Staszczak A; Grochowska A; Olearska H; Hubalewska-Dydejczyk A
Front Oncol; 2021; 11():687925. PubMed ID: 34868906
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
Kaemmerer D; Prasad V; Daffner W; Hörsch D; Klöppel G; Hommann M; Baum RP
World J Gastroenterol; 2009 Dec; 15(46):5867-70. PubMed ID: 19998512
[TBL] [Abstract][Full Text] [Related]
8. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
[TBL] [Abstract][Full Text] [Related]
9. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?
Sowa-Staszczak A; Pach D; Stefańska A; Tomaszuk M; Lenda-Tracz W; Mikołajczak R; Pawlak D; Chrzan R; Gilis-Januszewska A; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
Nucl Med Rev Cent East Eur; 2011; 14(2):73-8. PubMed ID: 22219146
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
11. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
Løitegård T; Berntzen DT; Thiis-Evensen E
Ann Nucl Med; 2019 Mar; 33(3):147-152. PubMed ID: 30406360
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
13. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW; Hofman MS; Thomson BN; Hicks RJ
Eur J Surg Oncol; 2012 Jan; 38(1):64-71. PubMed ID: 21906907
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
[TBL] [Abstract][Full Text] [Related]
15. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.
Kim SJ; Pak K; Koo PJ; Kwak JJ; Chang S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1964-70. PubMed ID: 26253273
[TBL] [Abstract][Full Text] [Related]
17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
Alsadik S; Yusuf S; Al-Nahhas A
Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
[TBL] [Abstract][Full Text] [Related]
19. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]